#1 Clinical Trials Search in Europe

Dapagliflozin Propanediol

This article examines the use of Dapagliflozin Propanediol, a medication known as an SGLT2 inhibitor, in various clinical trials. These studies investigate its effects on heart conditions, kidney function, and diabetes management. The trials cover a range of doses and patient populations, providing insights into the drug’s potential benefits and safety profile across different medical conditions.

Table of Contents

What is Dapagliflozin?

Dapagliflozin, also known by its brand names Forxiga or Farxiga, is a medication primarily used to treat type 2 diabetes and certain heart conditions[1]. It belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors[1]. This medication works in a unique way to help control blood sugar levels and has shown promising results in treating various cardiovascular and kidney-related conditions.

What Conditions Does Dapagliflozin Treat?

Dapagliflozin is used to treat several conditions, including:

  • Type 2 Diabetes: This is the primary condition for which dapagliflozin was initially developed[1].
  • Heart Failure: Recent studies have shown that dapagliflozin can be beneficial for patients with heart failure, particularly those with reduced ejection fraction (HFrEF)[4]. Ejection fraction refers to how much blood the heart pumps out with each beat.
  • Chronic Kidney Disease: Dapagliflozin has shown promise in slowing the progression of kidney disease in some patients[1].
  • Cardiovascular Disease: The medication has demonstrated benefits in reducing the risk of cardiovascular events in patients with type 2 diabetes[4].

How Does Dapagliflozin Work?

Dapagliflozin works by inhibiting the SGLT2 protein in the kidneys[1]. Here’s a simplified explanation of its mechanism:

  1. Blocking glucose reabsorption: SGLT2 is responsible for reabsorbing glucose in the kidneys. By blocking this protein, dapagliflozin prevents the kidneys from reabsorbing glucose back into the bloodstream.
  2. Increasing glucose excretion: As a result, more glucose is excreted through urine, which helps lower blood sugar levels.
  3. Reducing strain on the heart and kidneys: By promoting glucose excretion, dapagliflozin may help reduce the workload on these vital organs, potentially explaining its benefits in heart and kidney conditions.

Dosage and Administration

Dapagliflozin is typically taken orally once daily. The dosage can range from very low doses (0.001 mg) in some research settings to the standard dose of 10 mg for most patients[5]. It’s important to note that the appropriate dosage may vary depending on the condition being treated and individual patient factors. Always follow your healthcare provider’s instructions regarding dosage and administration.

Benefits of Dapagliflozin

Research has shown several potential benefits of dapagliflozin:

  • Improved glycemic control: Dapagliflozin helps lower blood sugar levels in patients with type 2 diabetes[1].
  • Cardiovascular protection: Studies have demonstrated that dapagliflozin can reduce the risk of cardiovascular events and death in patients with heart failure[4].
  • Kidney function preservation: The medication may help slow the progression of kidney disease in some patients[1].
  • Weight loss: Some patients may experience modest weight loss while taking dapagliflozin[3].
  • Blood pressure reduction: Dapagliflozin may help lower blood pressure in some patients[3].

Potential Side Effects

While dapagliflozin is generally well-tolerated, it can cause some side effects. Common side effects may include[5]:

  • Increased urination
  • Urinary tract infections
  • Genital yeast infections
  • Low blood sugar (especially when combined with other diabetes medications)
  • Dehydration

It’s important to discuss any side effects with your healthcare provider. They can help determine if the benefits of the medication outweigh the risks for your specific situation.

Ongoing Research

Dapagliflozin continues to be the subject of numerous clinical trials exploring its potential benefits in various conditions. Some ongoing areas of research include:

  • Heart failure with preserved ejection fraction (HFpEF): Researchers are investigating whether dapagliflozin can benefit patients with this type of heart failure[4].
  • Kidney transplant patients: Studies are exploring the potential of dapagliflozin to improve outcomes in patients who have received kidney transplants[1].
  • Tricuspid regurgitation: This is a heart valve condition where researchers are studying if dapagliflozin can help improve heart function[2].
  • Cardiac remodeling after heart attack: Scientists are investigating whether dapagliflozin can help prevent harmful changes in heart structure and function following a heart attack[3].

These ongoing studies may lead to new approved uses for dapagliflozin in the future, potentially benefiting a wider range of patients.

Aspect Details
Drug Name Dapagliflozin Propanediol (also known as Forxiga, Farxiga, BMS-512148)
Drug Class SGLT2 inhibitor
Main Conditions Studied Tricuspid Regurgitation, Heart Failure, Left Ventricular Dysfunction, Type 2 Diabetes
Dosage Range 0.001 mg to 10 mg
Administration Oral (tablets or solution)
Key Outcome Measures Heart function (LVEF, RV volumes), Urinary glucose excretion, Blood volume status, Vascular function, Safety and tolerability
Trial Durations 2 days to 12 months
Patient Populations Healthy subjects, Patients with heart conditions, Diabetics

FAQ

  • What is Dapagliflozin Propanediol used for in clinical trials? Dapagliflozin Propanediol is being studied for various conditions including severe tricuspid regurgitation, heart failure, left ventricular dysfunction, and type 2 diabetes. It's being tested for its effects on heart function, kidney health, and blood sugar control.
  • How is Dapagliflozin Propanediol administered in these trials? The medication is typically given orally, either as tablets or oral solution. Doses range from ultra-low amounts like 0.001 mg up to 10 mg, depending on the specific trial and condition being studied.
  • What are some of the main outcomes being measured in these trials? Researchers are looking at various outcomes including changes in heart function (like left ventricular ejection fraction), urinary glucose excretion, blood volume status, and the occurrence of adverse events to assess safety and tolerability.
  • Are there any potential side effects of Dapagliflozin Propanediol mentioned in the trials? While specific side effects aren't detailed, the trials are monitoring for adverse events. One study mentions watching for symptoms of volume depletion, hypoglycemia, genital infections, and changes in liver function as potential side effects.
  • How long do these clinical trials typically last? The duration of the trials varies. Some last for just a few days to assess immediate effects, while others continue for several months (up to 12 months in some cases) to evaluate long-term impacts and safety.

Ongoing Clinical Trials on Dapagliflozin Propanediol

  • Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Dapagliflozin, Finerenone, and Semaglutide for Treating Chronic Kidney Disease in Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany Italy Spain Sweden

  • Study on Preventing Atrial Fibrillation Recurrence After Cardioversion Using Dapagliflozin in Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on Stopping Beta-Blockers in Heart Failure Patients with Recovered Heart Function Using Carvedilol and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study of semaglutide and dapagliflozin effects on heart muscle insulin resistance in patients with type 2 diabetes

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Comparison of dapagliflozin versus metformin treatment in patients with early stage type 2 diabetes to evaluate survival and complications

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

  • Study on the Effects of Dapagliflozin on Heart Function in Patients with Chronic Kidney Disease

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Hungary Poland Slovakia Spain

  • Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria Croatia Germany Greece Hungary Poland +3

  • Study on Starting Valsartan, Sacubitril, and Empagliflozin for Patients with Heart Failure with Reduced Ejection Fraction

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Portugal

Glossary

  • SGLT2 inhibitor: A type of medication that works by helping the kidneys remove excess sugar from the body through urine.
  • Tricuspid Regurgitation: A heart valve condition where the valve between the two right heart chambers doesn't close properly, causing blood to flow backward in the heart.
  • Left Ventricular Ejection Fraction (LVEF): A measurement of how much blood the left ventricle pumps out with each contraction, used to evaluate heart function.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Bioelectrical Impedance Analysis (BIA): A method to estimate body composition, particularly body fat and muscle mass, using the rate at which an electrical current travels through the body.
  • Cardio-pulmonary Exercise Test (CPET): A test that measures how well the heart, lungs, and muscles work during physical activity.
  • Acute Myocardial Infarction (AMI): The medical term for a heart attack, where blood flow to part of the heart is blocked, causing damage to the heart muscle.
  • Vena Contracta Width (VCW): A measurement used in echocardiography to assess the severity of valve regurgitation or leakage.
  • NT-proBNP: A hormone produced by the heart that is measured in the blood. Elevated levels can indicate heart failure or cardiac stress.

References

  1. https://clinicaltrials.gov/study/NCT04743453
  2. https://clinicaltrials.gov/study/NCT05686616
  3. https://clinicaltrials.gov/study/NCT05418946
  4. https://clinicaltrials.gov/study/NCT04869124
  5. https://clinicaltrials.gov/study/NCT01135446